Pfizer Corporation Hong Kong Limited 美國輝瑞科研製藥

dynastat_product

Indication¹

Management of acute and postoperative pain.

Clinical Evidence

Effective postoperative pain relief and reduced opioid use vs placebo^2-5

Safety Profile¹

CI:	Hypersensitivity to sulphonamides, nonsteroidal anti-inflammatory drugs (NSAIDs) or other COX-2 selective inhibitors. Severe hepatic impairment, active peptic ulceration or gastrointestinal (GI) bleeding, inflammatory bowel disease, severe congestive heart failure. Pregnancy (3^rd trimester) and lactation.

SP:	Caution if used to treat post-coronary artery bypass graft (CABG) pain. Hepatic or renal impairment, hypertension, compromised cardiac function, conditions predisposing to fluid retention. Dehydration, history of upper GI perforations, ulcers or bleeds. May mask fever.

AR:	Blood pressure changes, back pain, peripheral oedema, numbness, GI disturbances, renal impairment, agitation, insomnia, anaemia, sore throat, difficulty in breathing, pruritus, oliguria.

DI:	Fluconazole, angiotensin-converting enzyme (ACE) inhibitors, diuretics, antihypertensives, cyclosporin, tacrolimus, warfarin, lithium, rifampicin, phenytoin, carbamazepine, dexamethasone, methotrexate, substrates of CYP2C19 and CYP2D6.

Dosages¹

Initially, 40 mg IM/IV followed by 20–40 mg 6–12 hours later if required.
Max: 80 mg in 24 hours.

Strengths¹

40 mg.

Packing¹

Vial 40 mg x 5's.

References

1. MIMS Annual Hong Kong. 2007/2008 edition.
2. Ott E, et al. J Thorac Cardiovasc Surg 2003;125:1481-1492.
3. Hubbard RC, et al.   Br J Anaesth 2003;90:166-172.
4. Tang J, et al.   Anesthesiology 2002;96:1305-1309.
5. Malan TP Jr, et al.   Anesthesiology 2003;98:950-956.

Please review the full product information or package insert before prescribing.